BioInvent International
28.10.2021 08:31:40 CEST | ACCESS Newswire | Press release
LUND, SWEDEN / ACCESSWIRE / October 28, 2021 / BioInvent International (STO:BINV)
"The powerful combination of BioInvent's R&D and in-house manufacturing provides invaluable support to our clinical development and facilitates the execution of our current clinical portfolio. The integration of functions, on top of world leading science, makes it possible for us to develop novel treatments for patients suffering from serious diseases. The solid balance sheet and strong, loyal shareholders support us in achieving our goals," said Martin Welschof, BioInvent CEO.
Events in the quarter
• (R) BioInvent announced a second clinical trial collaboration and supply agreement with Merck to evaluate BI-1808 in combination with Keytruda® (pembrolizumab) in patients with advanced solid tumors.
• Emma Meurling joined Bioinvent as Human Resource (HR) Director.
Events after the period
• BioInvent and Transgene announced that preclinical data for BT-001, a novel oncolytic virus delivering an anti-CTLA-4 antibody for the treatment of solid tumors, will be presented at SITC in November 2021.
• New data on the lead drug candidate BI-1206 Phase 1/2a study in non-Hodgkin's lymphoma (NHL) to be presented at the ASH (American Society of Hematology) conference December 11-14.
• New production agreement with CRUK to produce additional batch of anti-HER3 antibody.
• Prof. Eggermont new member of the BioInvent Scientific Advisory Board.
Financial information
Third quarter 2021
• Net sales SEK 3.0 (16.3) million.
• Loss after tax SEK -62.6 (-32.9) million.
• Loss after tax per share before and after dilution SEK -1.07 (-1.00).
• Cash flow from operating activities -57.5 (-31.4) million.
January - September 2021
• Net sales SEK 14.5 (48.6) million.
• Loss after tax SEK -199.7 (-104.9) million.
• Loss after tax per share before and after dilution SEK -3.79 (-4.00).
• Cash flow from operating activities SEK -170.1 (-91.8) million.
• Liquid funds and long-term investments as of September 30, 2021: SEK 1,445.3 (642.1) million.
The complete report is attached as pdf and is available on the company's website www.bioinvent.com/investors/#financialreports.
(R)= Regulatory event
Contacts
Cecilia Hofvander
Senior Director Investor Relations
Tel: +46 46 286 85 50
Email. cecilia.hofvander@bioinvent.com
About Us
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.
Attachments
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/670065/BioInvent-International-AB-Interim-Report-January--September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Files Interim Financial Statements for the Six Months Ended July 31, 202630.9.2026 00:45:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / September 29, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTC PINK:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the six-month period ended July 31, 2026, available for viewing on www.sedarplus.ca. Financial HighlightsTotal assets as at July 31, 2026 of $35,465,204Total cash as at July 31, 2026 of $422,500Working capital deficiency as at July 31, 2026 of $3,188,114Shareholder's equity as at July 31, 2026 of $31,803,864 During the six-month period ended July 31, 2026, the Company incurred $164,309 in cost for exploration activities at the Thunder Bay North project. During the second fiscal quarter, the Company focused on finalizing the proposed amalgamation while continuing discussions on Advanced Exploration permitting and re-assessment of past geophysical work to highlight areas of focus for drilling and geophysics in
Continent 8 and FuturePath AI Launch Future8: Accountable AI for Regulated Industries29.9.2026 15:00:00 CEST | Press release
LISBON, PT / ACCESS Newswire / September 29, 2026 / Continent 8 Technologies and FuturePath AI today launched Future8, an AI-native operating company built for regulated operators, formed as a joint venture between the two companies. Announced at SBC Summit Lisbon, Future8 combines FuturePath's enterprise AI applications platform with Continent 8's licensed global operating footprint, enabling the iGaming industry to deploy auditable AI without compromising compliance, data sovereignty and operational control. Built for highly regulated environments, Future8 enables operators to move from AI experimentation to production deployment by embedding governance, approvals and auditability into every workflow from day one. Continent 8 brings licensed data centers and a private global network spanning more than 100 locations, built over 28 years serving the biggest iGaming and online brands, along with AI-enabled Global Capability Centers in India, the Philippines and Bulgaria. The company als
Europe SPAC Summit 2026 Invites European Private Companies to Explore the SPAC Path to U.S. Public Markets29.9.2026 15:00:00 CEST | Press release
NEW YORK, NY AND ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2026 / A growing number of European companies in frontier technologies, critical minerals, advanced manufacturing, defense tech, energy, and consumer sectors are evaluating a merger with a special purpose acquisition company (SPAC) as a faster route to a U.S. listing, a valuation that reflects global investor demand, and access to follow-on capital. The Europe SPAC Summit 2026 (ESPAC'26), co-hosted by AUM Advisors and MBP Global, is inviting the CEOs, CFOs, founders, and board members of late-stage European private companies to The Dolder Grand in Zurich on Thursday, December 10, 2026, to learn how the process works and to meet the investment bankers, institutional investors, and SPAC sponsors who make these transactions happen. Attendance is by invitation only and free of charge for qualified companies. Europe's recent de-SPACs show what is possible. Kyivstar, Ukraine's largest mobile operator, listed on Nasdaq thr
Gedeon Richter Launches Online Platform for Transdiagnostic Global Impression Scales and New Caregiver Book at Next Step Conference29.9.2026 14:00:00 CEST | Press release
BUDAPEST, HU / ACCESS Newswire / September 29, 2026 / Gedeon Richter welcomed 145 participants from 27 countries to the latest edition of Next Step, the company's international conference for psychiatrists, held in September at the Hungarian Academy of Sciences. "At Gedeon Richter, we see partnerships as a cornerstone of advancing psychiatric care. By supporting healthcare professionals, patients, and caregivers alike, we can help create meaningful improvements in outcomes, functioning, and quality of life for people living with mental health conditions," said Kristóf Kóczián, Head of Global Business Development and CNS Business Unit at Gedeon Richter in his opening speech. The scientific programme explored how psychiatric care can move beyond diagnostic labels and adopt a more personalized, measurement-based approach. The presentations highlighted how personalized, measurement-based care can be integrated into everyday clinical practice, with a focus on cognitive symptoms, treatment-r
U.S. Polo Assn. Brings 'Game On' to Life with the 2026 Fall-Winter Global Collection29.9.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / September 29, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), has launched its 2026 Fall-Winter Global Collection, a modern expression of American style rooted in the heritage and energy of the sport of polo. Photographed in the beautiful countryside of Millbrook, New York, the campaign blends the sophistication of New York lifestyle with the authenticity of Hudson Valley's equestrian heritage. From local gathering places and small-town Americana to scenic polo fields and countryside settings, the location creates a natural backdrop for ‘Game On,' a seasonal story inspired by campus life, sport, and polo's enduring style. "The 2026 Fall-Winter Global Collection reflects what makes U.S. Polo Assn. distinctive: an authentic connection to the sport, a modern American point of view and style designed for real life," said J. Michael Prince, President and CEO of USPA Global, the company that manages and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom